FindTrial
Sign In

Relationship between KLB, FGF19 and liver disease

The relationship between KLB, FGF19 and HBV-associated liver disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058842
Enrollment
Unknown
Registered
2022-04-17
Start date
2022-04-24
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B associated liver disease

Interventions

Healthy control:None
Chronic hepatitis B:None
CHB-cirrhosis:None
CHB-HCC:None

Sponsors

Chongqing University Three Gorges Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 18 and 65 (including 18 and 65), with no gender limitation; 2. Meet the diagnostic criteria for chronic hepatitis B (HBsAg or HBV DNA positive for more than 6 months, or confirmed by liver biopsy).

Exclusion criteria

Exclusion criteria: 1. Autoimmune liver disease (ANA > 1/320), alcoholic hepatitis, drug and toxic liver injury, and other diseases that can cause significant liver damage; 2. Acute cardio-cerebrovascular accident and/or extrahepatic end-stage disease; 3. Pregnant, parturient or lactating women; 4. Other conditions considered unsuitable for inclusion by other researchers.

Design outcomes

Primary

MeasureTime frame
Fibroblast growth factor 19 and its coreceptor KLB;—

Secondary

MeasureTime frame
Hepatic function index;Serum markers for live fibrosis;Normal blood lipid;Blood routine examination;—

Countries

China

Contacts

Public ContactWu Guicheng

Chongqing University Three Gorges Hospital

351094703@qq.com+86 13896208811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026